Navigation Links
Prostate cancer screening: New data support watchful waiting
Date:8/13/2013

PHILADELPHIA Prostate cancer aggressiveness may be established when the tumor is formed and not alter with time, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.

Researchers found that after the introduction of widespread prostate-specific antigen (PSA) screening, the proportion of patients diagnosed with advanced-stage cancers dropped by more than six-fold in 22 years, but the proportion diagnosed with high Gleason grade cancers did not change substantially. This suggests that low-grade prostate cancers do not progress to higher grade over time.

Cancer stage refers to the extent or spread of the disease, and cancer grade, called Gleason grade for prostate cancer, refers to the aggressiveness of the disease.

"We were able to look at finely stratified time periods to capture pre-PSA, early-PSA, and late-PSA eras within one study. Over time, because of PSA screening, men have been more likely to be diagnosed with prostate cancer at an earlier stage, before the disease has had an opportunity to grow and spread. If Gleason grade also progressed over time, we would expect a similar decrease in high Gleason grade disease over time," said Kathryn Penney, Sc.D., instructor in medicine at the Harvard Medical School and associate epidemiologist at the Channing Division of Network Medicine at Brigham and Women's Hospital in Boston, Mass. "We were surprised by just how constant the incidence of high-grade disease has been over time."

This study adds more evidence to the argument that patients who are diagnosed with low-grade prostate cancers can opt for an active surveillance, or "watch and wait" approach instead of getting treated right away.

Penney and colleagues used data from 420 participants recruited to the Physicians' Health Study and 787 participants recruited to the ongoing Health Professionals Follow-up Study. All participants were diagnosed with prostate cancer between 1982 and 2004, and treated with surgery. The researchers reanalyzed prostate tissue collected from these patients to assess Gleason grade.

The researchers divided the data into four time periods based on when the participants received a diagnosis and treatment: 1982-1993, 1993-1996, 1996-2000, and 2000-2004, to represent the pre-PSA and PSA eras. They found that the number of participants who had undergone PSA screening increased from 42 percent in 1994 to 81 percent in 2000.

They also found that the number of late-stage cancers decreased from 19.9 percent in the 1982-1993 group to just 3 percent in the 2000-2004 group, reflecting an 85 percent drop in stage at diagnosis. However, there was only a moderate decrease in high Gleason grade cancers, from 25.3 percent in the 1982-1993 group to 17.6 percent in the 2000-2004 group, reflecting a 30 percent drop.

With further analyses, the researchers found that the moderate drop in high Gleason grade cancers was not because progression to more aggressive disease was prevented through screening, but because of an increased diagnosis of low-grade disease that would not have been detected without PSA screening.

"Radical prostatectomy or radiation therapy, the usual treatments for prostate cancer, can have negative side effects such as impotence and incontinence; choosing active surveillance could prevent this decline in quality of life," said Penney. "Men with low-grade disease at diagnosis should seriously consider talking with their doctors about active surveillance."


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Intensity Modulated Radiation Therapy optimal for localized prostate cancer
4. Study examines adverse effects among different radiation therapies for prostate cancer
5. Study Casts Doubt on Value of Pricey Prostate Cancer Therapy
6. Warren Buffett Has Early Stage Prostate Cancer
7. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
8. PSA screening to detect prostate cancer can be beneficial to younger and at-risk men
9. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
10. Quality of care, other issues may cause worse results in black prostate cancer surgery patients
11. Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... (PRWEB) , ... August 20, 2017 , ... Are you ... same household? If so, you may be interested in participating in a research ... of this research is to understand more about the relational aspects of adults who ...
(Date:8/19/2017)... ... 2017 , ... Western University of Health Sciences will host a special symposium ... Center for Innovation on Wednesday, September 6, 2017. , The symposium will be from ... a technology exhibition from 1 to 3 p.m. showcasing virtual reality education technology, high ...
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... ... Drug Administration Reauthorization Act of 2017, legislation that provides for greater public access ... to moderate hearing loss to access OTC hearing aids without being seen by ...
(Date:8/19/2017)... , ... August 19, 2017 , ... Curl Keeper® is ... NaturallyCurly.com® The Curl Leaders, Editors’ Choice 2017 Award for the second year in a ... hair stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies and ...
(Date:8/19/2017)... ... ... Yesterday, the President of the United States retracted his condemnation of white ... two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. That ... all forms of such hatred and discrimination in this country and globally. ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... June 30, 2017, and updated its financial outlook for ... For the fiscal third quarter, Hill-Rom reported earnings of ... share in the prior-year period. These results reflect after-tax ... share primarily related to the non-cash write-down of assets ...
Breaking Medicine Technology: